Affiliation:
1. PathoGuard Consult Seeheim‐Jugenheim Germany
Abstract
AbstractThe capacity to remove viruses by Planova filters produced by Asahi Kasei, primarily by small virus‐retentive filters, were compiled from data in peer‐reviewed publications and, partly, publicly available data from presentations at conferences (Planova workshops). Data from more than 100 publications and presentations at conferences covering Planova filters were assessed. The data were grouped according to the different virus filters regarding mean pore sizes and viruses of different sizes for plasma and cell culture derived products. Planova 15N and 20N filters removed parvoviruses below the limit of detection of viruses in the filtrate in approx. 50% of all studies and mean LRFs (log reduction factors) for viruses detected in the filtrate were above 4, demonstrating effective parvovirus reduction. Parvovirus removal capacity increased for Planova BioEX filters as well as for 2 Planova 20N in series. Large viruses as retroviruses (e.g., HIV and MuLV), herpesviruses, flaviviruses and togaviruses were removed effectively by Planova 15N, 20N and BioEX filters and also by Planova 35N filters. Flow interruption, transmembrane pressure, volume and protein concentration per filter area had had no substantial impact on virus removal capacity at manufacturing specification. In conclusion, the incorporation of Planova filters in manufacturing processes of biologicals remove, depending on the filter pore size, small and large viruses from the feed stream reliably. This virus reduction step with an orthogonal mechanism integrated in the manufacturing processes of biologicals, based primarily on size exclusion of viruses, improves the virus safety of these biopharmaceutical products considerably.
Reference49 articles.
1. EMA/CHMP/BWP/706271/2010.Guideline on plasma‐derived medicinal products. European Medicines Agency (EMA); 21 July.2011https://www.ema.europa.eu/documents/scientific-guideline/guideline-plasma-derived-medicinal-products_en.pdf
2. PPTA.Safety & Quality Standards Programs—International Quality Plasma Program (IQPP) and Quality Standards of Excellence Assurance & Leadership (QSEAL).https://www.pptaglobal.org/safety-quality/standards
3. ICH Q5A(R1).Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. Current Step 4 version dated 23 September.1999https://database.ich.org/sites/default/files/Q5A%28R1%29%20Guideline_0.pdf
4. Virus Retentive Filtration.Technical report No. 41 (Revised 2022). Parenteral Drug Association.2022.
5. Virus filtration: A review of current and future practices in bioprocessing